Total Valuation
United Therapeutics has a market cap or net worth of CHF18.33B. The enterprise value is CHF22.15K.
Market CapCHF18.33B
Enterprise ValueCHF22.15K
Share Statistics
United Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.95%
Owned by Institutions24.43%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.13%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)16.13%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee2.27M
Profits Per Employee953.36K
Employee Count1,400
Asset Turnover0.40
Inventory Turnover2.10
Valuation Ratios
The current PE Ratio of United Therapeutics is 17.1. United Therapeutics’s PEG ratio is 1.16.
PE Ratio17.1
PS Ratio6.78
PB Ratio3.04
Price to Fair Value3.04
Price to FCF20.74
Price to Operating Cash Flow13.03
PEG Ratio1.16
Income Statement
In the last 12 months, United Therapeutics had revenue of 3.18B and earned 1.33B in profits. Earnings per share was 30.13.
Revenue3.18B
Gross Profit2.80B
Operating Income1.52B
Pretax Income1.71B
Net Income1.33B
EBITDA1.82B
Earnings Per Share (EPS)30.13
Cash Flow
In the last 12 months, operating cash flow was 1.69B and capital expenditures -592.20M, giving a free cash flow of 1.09B billion.
Operating Cash Flow1.69B
Free Cash Flow1.09B
Free Cash Flow per Share10.00T>
Dividends & Yields
United Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
United Therapeutics upcoming earnings date is Nov 4, 2026, Before Open (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 4, 2026
Ex-Dividend Date―
Financial Position
United Therapeutics as a current ratio of 6.60, with Debt / Equity ratio of 0.00%
Current Ratio6.60
Quick Ratio6.28
Debt to Market Cap0.00
Net Debt to EBITDA-0.84
Interest Coverage Ratio77.81
Taxes
In the past 12 months, United Therapeutics has paid 379.20M in taxes.
Income Tax379.20M
Effective Tax Rate0.22
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 11.03, with an EV/FCF ratio of 19.28.
EV to Sales6.30
EV to EBITDA11.03
EV to Free Cash Flow19.28
EV to Operating Cash Flow12.85
Balance Sheet
United Therapeutics has CHF2.66B in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF2.66B billion.
Cash & Marketable SecuritiesCHF2.66B
Total DebtCHF0.00
Net CashCHF2.66B
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF157.56
Margins
Gross margin is 86.14%, with operating margin of 47.67%, and net profit margin of 41.94%.
Gross Margin86.14%
Operating Margin47.67%
Pretax Margin53.85%
Net Profit Margin41.94%
EBITDA Margin57.15%
EBIT Margin54.46%
Analyst Forecast
The average price target for United Therapeutics is CHF525.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF525.25
Price Target Upside― Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―